April 2016, Volume 2, Issue 4

April 2016

Volume 2, Issue 4

This issue features a look at how living with severe hemophilia changed in the last 50 years, weighing the risks and rewards of standardizing care, and a How I Teach piece on the coagulation cascade.

Table of Contents

April 2016

Being a Patient Advocate: The Balance of Helping without Hurting

Friday, April 1st, 2016
Engaging in patient advocacy is a rewarding activity and allows health-care providers to assist patients in asserting their rights and maintaining control over their...

How would you treat a patient with Wilson’s disease and neutropenia?

Friday, April 1st, 2016
Here's how readers responded to a You Make the Call question about a patient with Wilson’s disease and neutropenia? Disclaimer: ASH does not recommend or endorse...

Why Did You Become a Hematologist?

Friday, April 1st, 2016
I am truly curious as to why doctors in training choose a career in hematology, particularly malignant hematology. My ASH Clinical News editorial colleague, David...

April 2016

A Call for a Uniform Subspecialty Fellowship Training Start Date, Choosing Wisely Champions, and...

Friday, April 1st, 2016
ASH Supports the Call for a Uniform Subspecialty Fellowship Training Start Date According to the Alliance for Academic Internal Medicine’s (AAIM) white paper: “At present,...

April 2016: Remembering Holbrook Kohrt, NHLBI Awards, and more

Friday, April 1st, 2016
Holbrook Kohrt, MD, PhD (1977–2016) Holbrook Kohrt, MD, PhD, a noted clinician-researcher at Stanford Medicine dedicated to finding novel ways to arm the immune system...

April 2016

PASHions - Elizabeth Brem

Staying En Pointe: Elizabeth Brem, MD

Friday, April 1st, 2016
When did you start dancing? I started dancing when I was about five years old. My parents were looking for an outlet for my energy,...
Dr. Tallman with his wife, Wendy, and their four children (Jacob, Sarah, Miriam, and Sam) at a Michigan football game.

Pulling Back the Curtain: Martin S. Tallman, MD

Friday, April 1st, 2016
What was your first job? I grew up in the northern suburbs of Chicago, and was a paperboy in elementary school. During the summers, I...

Finding the Care Path of Least Resistance: Weighing the Risks and Rewards of Standardizing...

Friday, April 1st, 2016
Greater exploration of the “hows,” the “whys,” and the heterogeneity of hematologic conditions in recent years has led to greater variety of treatments available...

April 2016

How I Teach the Coagulation Cascade

Friday, April 1st, 2016
In this issue, Alice Ma, MD, shares her advice for teaching the coagulation cascade – to hematologists and non-hematologists, medical students, and attendings. Why is...

How would you treat a patient with Wilson’s disease and neutropenia?

Friday, April 1st, 2016
This month, Stanley L. Schrier, MD, answers a question about a patient with Wilson's disease and neutropenia.I was asked to see a 41-year-old male with Wilson’s...

April 2016

FDA Approves New Agent to Prevent Delayed Nausea in Patients Receiving Emetogenic Chemotherapy

Friday, April 1st, 2016
The U.S. Food and Drug Administration (FDA) approved single-dose fosaprepitant dimeglumine injection in combination with other anti-emetic agents for the prevention of delayed nausea...

HHS Announces Plan to Improve EHR Information Flow

Friday, April 1st, 2016
The U.S. Department of Health & Human Services (HHS) announced an initiative to make electronic health records (EHRs) more easily accessible and useful for...

Examining a PET-Response–Adapted Strategy in Patients with Advanced Hodgkin Lymphoma

Friday, April 1st, 2016
Positron emission tomography (PET) performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma (HL) can identify patients who would benefit from therapy...

FDA Issues Recommendations to Reduce the Risk of Zika Virus Transmission Through Blood and...

Friday, April 1st, 2016
The U.S. FDA announced new safety recommendations to reduce the risk of transmission of the Zika virus through human cell and tissue donations. The...

FDA Providing $2 Million in New Grants for Rare Disease Research

Friday, April 1st, 2016
The U.S. FDA’s Office of Special Medical Programs/Office of Orphan Products Development (OSMP/OOPD) has launched a new grants program that will provide $2 million...
WIB_icon

Report Questions the Validity of Rivaroxaban Trial

Friday, April 1st, 2016
An investigation by the British Journal of Medicine (BMJ) has raised questions about the validity of the pivotal ROCKET-AF trial, the results of which formed the...

White House, NIH Announce Progress in Precision Medicine Projects

Friday, April 1st, 2016
The White House and the National Institutes of Health (NIH) announced that enrollment of volunteers into the Precision Medicine Initiative (PMI) Cohort Program has...

Midostaurin Receives Breakthrough Therapy Designation

Friday, April 1st, 2016
The U.S. FDA granted breakthrough therapy designation to midostaurin, an oral, multi-targeted kinase inhibitor for adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML)...
WIB_icon

Does Cytomegalovirus Reactivation Protect Against AML Relapse?

Friday, April 1st, 2016
There is conflicting evidence regarding the role that cytomegalovirus (CMV) reactivation plays in the relapse risk of acute myeloid leukemia (AML) patients after they...

Is Minimal Residual Disease a Better Prognostic Factor than Genetic Markers in AML?

Friday, April 1st, 2016
In patients with high-risk acute myeloid leukemia (AML), often defined by cytogenetic and/or molecular factors, allogeneic hematopoietic cell transplantation (AlloHCT) is recommended in first...
WIB_icon

Can Cyclophosphamide Plus Pomalidomide and Dexamethasone Overcome Lenalidomide Resistance in Patients with Relapsed/Refractory Myeloma?

Friday, April 1st, 2016
Adding cyclophosphamide to the treatment combination of pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM) resulted in a superior overall response rate...

Multiple Myeloma Cytogenetics Do Not Differ Based on Race

Friday, April 1st, 2016
Though black patients have an incidence of multiple myeloma (MM) that is twice that of white patients, on average their overall survival is better....

Lenalidomide Plus R-CHOP in DLBCL, New Gene Therapies for Hemophilia B , and more

Friday, April 1st, 2016
LEUKEMIA David Steensma, MD Dana-Farber Cancer Institute A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3...

Blinatumomab Demonstrates Durable Complete, Partial Responses in Relapsed/Refractory Non-Hodgkin Lymphoma

Friday, April 1st, 2016
In a recent open-label, multicenter, dose-escalation, phase I study of blinatumomab in heavily pretreated patients with relapsed/refractory non-Hodgkin lymphoma (NHL), patients treated with the...
WIB_icon

How Has Living With Severe Hemophilia Changed in the Last 50 Years? An Analysis...

Friday, April 1st, 2016
In an analysis of data from nearly 5,000 men with severe hemophilia collected over the last half century, researchers have illustrated the experience of...

Caplacizumab Resolves TTP Episodes Quickly, Though Bleeding Risk is Increased

Friday, April 1st, 2016
Caplacizumab, an investigational anti-von Willebrand factor humanized single-variable-domain immunoglobulin, led to a more rapid resolution of thrombotic thrombocytopenia purpura (TTP) episodes than placebo, according...
WIB_icon

Study Examines Low-Dose Vemurafenib in Patients with Hairy Cell Leukemia

Friday, April 1st, 2016
A long-term, retrospective follow-up of 21 patients with refractory classic hairy cell leukemia (HCL) indicated that low doses of the BRAF inhibitor vemurafenib are...

April 2016

SHARE